Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 250K | 33K |
| Gross Profit | 0 | -119K | -742K | -301K | -695K |
| Operating Income | -12M | -9M | -8M | -14M | -13M |
| EBITDA | -12M | -9M | -8M | -14M | -12M |
| Net Income | -11M | -8M | -6M | -14M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.40
+0.00% today
1Y Change
-74.22%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Soligenix, Inc. (SNGX) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.40 and down 74.2% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +57.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +57.0%, free cash flow -22.2% with operating margin 0.0% and ROIC -205.5%. Stock Foundry combines SNGX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNGX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNGX Max Drawdown
-94.35%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNGX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$33.4K
-86.7% YoY
FY Net Income
-$12.6M
+9.0% YoY
Free Cash Flow
-$11.8M
+7.2% YoY
Revenue Growth
+0.0%
EPS Growth
+57.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 250K | 33K |
| Gross Profit | 0 | -119K | -742K | -301K | -695K |
| Operating Income | -12M | -9M | -8M | -14M | -13M |
| EBITDA | -12M | -9M | -8M | -14M | -12M |
| Net Income | -11M | -8M | -6M | -14M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8M | 8M | 8M | 13M | 26M |
| Total Assets | 9M | 9M | 10M | 14M | 27M |
| Total Liabilities | 4M | 5M | 7M | 17M | 16M |
| Shareholder Equity | 5M | 4M | 3M | -2M | 11M |
| Total Debt | 358K | 1M | 3M | 10M | 10M |
| Net Debt | -8M | -6M | -5M | -3M | -16M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
+7.2% YoY
Capital Expenditures
12K
+9.8% YoY
Free Cash Flow
12M
+7.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-248.0%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.